Eleven Biotherapeutics Announces First Patients Dosed with EBI-005 in Phase 3 Study in Patients with Moderate to Severe Allergic Conjunctivitis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Patient dosing in this study represents a significant step forward in the development of EBI-005, a drug candidate with potential for the treatment of moderate to severe allergic conjuctivitis.

Full Story →